96 related articles for article (PubMed ID: 29472546)
1. CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL.
Kim JH; Kim WS; Ryu KJ; Kim SJ; Park C
Blood Cancer J; 2018 Feb; 8(2):23. PubMed ID: 29472546
[No Abstract] [Full Text] [Related]
2. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.
Paul J; Soujon M; Wengner AM; Zitzmann-Kolbe S; Sturz A; Haike K; Keng Magdalene KH; Tan SH; Lange M; Tan SY; Mumberg D; Lim ST; Ziegelbauer K; Liu N
Cancer Cell; 2017 Jan; 31(1):64-78. PubMed ID: 28073005
[TBL] [Abstract][Full Text] [Related]
4. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
5. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
[TBL] [Abstract][Full Text] [Related]
6. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
Du H; Gao L; Luan J; Zhang H; Xiao T
Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
[TBL] [Abstract][Full Text] [Related]
7. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
[TBL] [Abstract][Full Text] [Related]
8. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
9. [Expressions of VEGF and CXCR4 in diffuse large B cell lymphoma and their clinical significances].
Guo Q; Wang JJ; Li F; Yang HL; Yu Y; Zhao ZG; Wang XF; Wang YF; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):383-6. PubMed ID: 23628037
[TBL] [Abstract][Full Text] [Related]
10. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
Dubanet L; Bentayeb H; Petit B; Olivrie A; Saada S; de la Cruz-Morcillo MA; Lalloué F; Gourin MP; Bordessoule D; Faumont N; Delage-Corre M; Fauchais AL; Jauberteau MO; Troutaud D
Br J Cancer; 2015 Sep; 113(6):934-44. PubMed ID: 26284337
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
[TBL] [Abstract][Full Text] [Related]
12. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens.
Young RM; Wu T; Schmitz R; Dawood M; Xiao W; Phelan JD; Xu W; Menard L; Meffre E; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Staudt LM
Proc Natl Acad Sci U S A; 2015 Nov; 112(44):13447-54. PubMed ID: 26483459
[TBL] [Abstract][Full Text] [Related]
13. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.
Lam LT; Davis RE; Pierce J; Hepperle M; Xu Y; Hottelet M; Nong Y; Wen D; Adams J; Dang L; Staudt LM
Clin Cancer Res; 2005 Jan; 11(1):28-40. PubMed ID: 15671525
[TBL] [Abstract][Full Text] [Related]
16. Aberrant localization of apoptosis protease activating factor-1 in lipid raft sub-domains of diffuse large B cell lymphomas.
Hirpara JL; Loh T; Ng SB; Chng WJ; Pervaiz S
Oncotarget; 2016 Dec; 7(51):83964-83975. PubMed ID: 27863378
[TBL] [Abstract][Full Text] [Related]
17. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
[TBL] [Abstract][Full Text] [Related]
18. Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition.
Shi X; Lan X; Chen X; Zhao C; Li X; Liu S; Huang H; Liu N; Zang D; Liao Y; Zhang P; Wang X; Liu J
Sci Rep; 2015 Apr; 5():9694. PubMed ID: 25853502
[TBL] [Abstract][Full Text] [Related]
19. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.
He S; Miao X; Wu Y; Zhu X; Miao X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Wang Y; Xu X
J Cancer Res Clin Oncol; 2016 Mar; 142(3):561-72. PubMed ID: 26498772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
